A drug, currently used to treat bone metastases in patients with lung cancer, could also be useful to prevent the cancer from spreading in the first place, an Italian research has found.
Michela Quirino and colleagues from the Catholic University of the Sacred Heart in Rome have reported important new evidence that zoledronic acid may be able to prevent lung cancer metastases from recruiting the new blood vessels they need to survive.
"Our investigation represents the first clear clinical evidence of the anti-angiogenic effect of zoledronic acid in patients with metastatic lung cancer. It also represents the first biological basis in lung cancer for the clinical investigation of zoledronic acid not only for metastatic lung cancer, but also in early disease," said Quirino.
"We found a statistically significant reduction of VEGF levels at day 2 after 4 mg ZA intravenous infusion compared with basal values," said Quirino.
The researchers did not record any significant effect of injecting the drug on the levels of the other two mediators of angiogenesis, PDGF and HGF.
"If further studies should confirm a possible anti-metastatic effect of this drug, possibly relying also on its anti-angiogenic effect, it could be introduced in the early management of the disease, even as an adjuvant therapy," she said.